SLN Valuation

Silence Therapeutics PLC

Add to Watchlist

Advanced Chart

5.460

+0.13(2.439%)1D

Overview
Forecast
Valuation
Earnings

SLN Relative Valuation

SLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLN is overvalued; if below, it's undervalued.

Historical Valuation

Silence Therapeutics PLC (SLN) is now in the Fair zone, suggesting that its current forward PS ratio of 13.82 is considered Fairly compared with the five-year average of -14.70. The fair price of Silence Therapeutics PLC (SLN) is between 1.20 to 18.14 according to relative valuation methord.

Relative Value

Fair Zone

1.20-18.14

Current Price：5.33

Fair

-8.42

Trailing

Forward

-1.57

EV/EBITDA

Silence Therapeutics PLC. (SLN) has a current EV/EBITDA of -1.57. The 5-year average EV/EBITDA is -6.77. The thresholds are as follows: Strongly Undervalued below -18.34, Undervalued between -18.34 and -12.55, Fairly Valued between -0.99 and -12.55, Overvalued between -0.99 and 4.79, and Strongly Overvalued above 4.79. The current Forward EV/EBITDA of -1.57 falls within the Historic Trend Line -Fairly Valued range.

-1.56

EV/EBIT

Silence Therapeutics PLC. (SLN) has a current EV/EBIT of -1.56. The 5-year average EV/EBIT is -7.03. The thresholds are as follows: Strongly Undervalued below -17.27, Undervalued between -17.27 and -12.15, Fairly Valued between -1.91 and -12.15, Overvalued between -1.91 and 3.21, and Strongly Overvalued above 3.21. The current Forward EV/EBIT of -1.56 falls within the Overvalued range.

13.84

Silence Therapeutics PLC. (SLN) has a current PS of 13.84. The 5-year average PS is 27.77. The thresholds are as follows: Strongly Undervalued below -27.13, Undervalued between -27.13 and 0.32, Fairly Valued between 55.22 and 0.32, Overvalued between 55.22 and 82.66, and Strongly Overvalued above 82.66. The current Forward PS of 13.84 falls within the Historic Trend Line -Fairly Valued range.

-3.00

P/OCF

Silence Therapeutics PLC. (SLN) has a current P/OCF of -3.00. The 5-year average P/OCF is -24.03. The thresholds are as follows: Strongly Undervalued below -134.44, Undervalued between -134.44 and -79.23, Fairly Valued between 31.17 and -79.23, Overvalued between 31.17 and 86.37, and Strongly Overvalued above 86.37. The current Forward P/OCF of -3.00 falls within the Historic Trend Line -Fairly Valued range.

-2.63

P/FCF

Silence Therapeutics PLC. (SLN) has a current P/FCF of -2.63. The 5-year average P/FCF is -13.34. The thresholds are as follows: Strongly Undervalued below -40.72, Undervalued between -40.72 and -27.03, Fairly Valued between 0.35 and -27.03, Overvalued between 0.35 and 14.04, and Strongly Overvalued above 14.04. The current Forward P/FCF of -2.63 falls within the Historic Trend Line -Fairly Valued range.

Silence Therapeutics PLC (SLN) has a current Price-to-Book (P/B) ratio of 2.77. Compared to its 3-year average P/B ratio of 8.99 , the current P/B ratio is approximately -69.19% higher. Relative to its 5-year average P/B ratio of 17.51, the current P/B ratio is about -84.18% higher. Silence Therapeutics PLC (SLN) has a Forward Free Cash Flow (FCF) yield of approximately -33.51%. Compared to its 3-year average FCF yield of -16.13%, the current FCF yield is approximately 107.67% lower. Relative to its 5-year average FCF yield of -11.22% , the current FCF yield is about 198.53% lower.

2.67

P/B

Median3y

8.99

Median5y

17.51

-33.51

FCF Yield

Median3y

-16.13

Median5y

-11.22

Competitors Valuation Multiple

The average P/S ratio for SLN's competitors is 12.72, providing a benchmark for relative valuation. Silence Therapeutics PLC Corp (SLN) exhibits a P/S ratio of 13.84, which is 8.79% above the industry average. Given its robust revenue growth of -70.31%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SLN.O

Silence Therapeutics PLC

Information Services Group Inc

Performance Decomposition

Market capitalization of SLN decreased by 71.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.60K to -12.21K.

The secondary factor is the Revenue Growth, contributed -70.31%to the performance.

Overall, the performance of SLN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-70.31%

754.36K → 224.00K

Revenue Growth

369.25%

-2.60K → -12.21K

Margin Expansion

-370.34%

1.18 → -3.18

P/E Change

-71.40%